“Drawing Prada”: a celebration of craft and process. 
Created with the anachronistic technique of hand-drawn illustration, the Prada Holiday 2026 campaign invents an ensemble of whimsical characters and landscapes, starring Luther Ford, together with Prada Ambassadors Chen Haoyu, Maya Hawke, Kelvin Harrison Jr., and Sadie Sink. 
Discover the new Prada Holiday 2026 campaign: tinyurl.com/5a37d4wx   Creative Directors: #MiucciaPrada and #RafSimons 
Photographer: #GlenLuchford 
Animation Direction: #JohnPomeroy
Campaign Creative Direction: #FerdinandoVerderi 
Cast: #LutherFord #ChenHaoyu #MayaHawke #KelvinHarrisonJr #SadieSink     #PradaHoliday #PradaGifts #Prada

💥 Introducing Warp Sciences, a new company applying AI and robotics to help the world develop new medicines faster. We’ve raised a $215M Series A led by @lightspeedvp to bring frontier AI out of the browser and into the lab, and build scientific capacity here in America. I co-founded Warp with my long-time friend @dpatil, FAIR co-founder @manohar_paluri, and drug hunter Sol Reisberg. The early team is full of incredible people like @bkspears9, who helped achieve Q>1 fusion at LLNL.

In January 2025 my mom’s lung cancer spread to her brain. The drug with the best chance of helping her was approved in China but not here. A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy. So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years. The drug was approved in China in 2023. The FDA approved it in July 2025. It still is not for sale here. I know of at least 30 Americans who have made the same trip. I have been scared to tell this story because I worried it could cost my mom access to the medicine keeping her alive. But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform. Art Allen at KFF Health News told our story this week. It also ran in The Washington Post. kffhealthnews.org/health-ind…

In January 2025 my mom’s lung cancer spread to her brain. The drug with the best chance of helping her was approved in China but not here. A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy. So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years. The drug was approved in China in 2023. The FDA approved it in July 2025. It still is not for sale here. I know of at least 30 Americans who have made the same trip. I have been scared to tell this story because I worried it could cost my mom access to the medicine keeping her alive. But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform. Art Allen at KFF Health News told our story this week. It also ran in The Washington Post. kffhealthnews.org/health-ind…

We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! openai.com/index/openai-to-a…

Congratulations to Dr. Dennis Slamon, recipient of the 2026 Albany Prize for groundbreaking discoveries that transformed how we understand and treat cancer. An incredible and well-deserved honor! bit.ly/4rTVB3k

BREAKING: The U.S. government, Google, Meta & Zuckerberg-backed @biohub are launching a $1.8B push to build the data layer for AI biology. The goal is to create the largest open, AI-ready biological dataset ever assembled, giving models the data needed to better predict how biology works & ultimately help treat disease. The coalition is massive: › Biohub committed $500M › DOE is investing $500M+ across measurement, modeling & compute › NIH is bringing $500M+ of federally funded datasets & repositories › Meta, Google DeepMind & @IsomorphicLabs are jointly investing another $300M This is effectively an infrastructure buildout for AI biology. Instead of just building bigger models, they’re attacking one of the biggest bottlenecks in biology AI today, generating standardized, high-quality biological data at massive scale & making it openly available to researchers. $1.8B committed to turning biology into something AI can increasingly model, predict & engineer.

🥰😍🥹